GenMark Diagnostics, Inc
GNMK
GNMK was delisted on the 21st of April, 2021.
110 hedge funds and large institutions have $214M invested in GenMark Diagnostics, Inc in 2020 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 30 increasing their positions, 36 reducing their positions, and 24 closing their positions.
4% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 24
1% less funds holding
Funds holding: 111 → 110 (-1)
17% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 36
19% less capital invested
Capital invested by funds: $266M → $214M (-$51.3M)
26% less call options, than puts
Call options by funds: $682K | Put options by funds: $917K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$4.19M |
| 2 |
Millennium Management
New York
|
+$3.55M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$3.25M |
| 4 |
NIM
Needham Investment Management
New York
|
+$3.04M |
| 5 |
EP
Eversept Partners
New York
|
+$2.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadian Capital Management
New York
|
-$9.51M |
| 2 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
-$4.7M |
| 3 |
JP Morgan Chase
New York
|
-$4.08M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.89M |
| 5 |
Morgan Stanley
New York
|
-$2.63M |
GNMK Hedge Fund Activity: Q1 2020 in Review
110 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in GenMark Diagnostics, Inc (GNMK) for Q1 2020, worth a combined $214M — down 19% from $266M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new GNMK positions and 24 closed out — a net gain of 1 holder — while 30 added to existing stakes and 36 trimmed.
The largest buyer was Portolan Capital Management, opening a new position worth an estimated $4.19M. The largest seller was Cadian Capital Management, cutting an estimated $9.51M.
- 110 institutional investors held GenMark Diagnostics, Inc (GNMK) as of Q1 2020, down from 111 in Q4 2019.
- Funds reported $214M of GenMark Diagnostics, Inc stock for Q1 2020, down 19% quarter-over-quarter.
- 25 funds opened new GenMark Diagnostics, Inc positions in Q1 2020 and 24 closed out, a net change of +1 holder.
- The largest GenMark Diagnostics, Inc buyer in Q1 2020 was Portolan Capital Management, an estimated $4.19M added.
- The largest GenMark Diagnostics, Inc seller in Q1 2020 was Cadian Capital Management, an estimated $9.51M sold.
Based on aggregated 13F filings for Q1 2020.